SEC Form 4 · accession 0001358403-19-000008

BELLICUM PHARMACEUTICALS, INC · BLCM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Principal Accounting Officer

Period of report

Jan 2, 2019

Accepted (ET)

Jan 4, 2019 · 4:03 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001358403

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jan 2, 2019	M	1,281	—	A	4,467	D
Common Stock	Jan 2, 2019	F	483	$3.33	D	3,984	D
Common Stock^F1	Jan 3, 2019	M	782	—	A	4,766	D
Common Stock	Jan 3, 2019	F	295	$3.20	D	4,471	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Stock Units^F1,F4	—	Jan 2, 2019	M	1,281	D	—	—	Common Stock	1,281	3,844	D
Restricted Stock Units^F1,F5	—	Jan 3, 2019	M	782	D	—	—	Common Stock	782	1,562	D

F1Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock.
F2Represents the number of shares withheld by and surrendered to the Issuer on January 2, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 2, 2018 for 5,125 shares.
F3Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 3,125 shares.
F4The RSUs vest in four equal annual installments beginning on January 2, 2019.
F5The RSUs vest in four equal annual installments beginning on January 3, 2018.